Trial Profile
Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in k-ras/b-raf wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or without bevacizumab in k-ras mutant patients as neoadjuvant treatment in patients with non- resectable colorectal liver metastases
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms AIO CELIM2-study
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 10 Feb 2020 Status changed from active, no longer recruiting to discontinued.
- 09 Sep 2019 Planned End Date changed from 1 Jul 2020 to 1 Dec 2020.